Intravenous immunoglobulin therapy for neurological disorders

Area of Science:

• Neurology
• Immunology
• Health Policy

Background:

• Intravenous immunoglobulin (IVIg) is a treatment for various neurological conditions.
• Adherence to established guidelines ensures appropriate and effective use of IVIg therapy.

Purpose of the Study:

• To assess the compliance of IVIg use for neurological conditions with Australian Health Minister's Advisory Council guidelines.
• To identify neurological conditions for which IVIg was used despite lacking strong evidence of benefit.

Main Methods:

• A retrospective review of patients receiving IVIg in Otago over 5.5 years.
• Data sourced from New Zealand Blood Service and hospital records.

Main Results:

• 57 of 200 patients had neurological conditions, including myasthenia gravis, Guillain-Barre syndrome, and multiple sclerosis.
• 31% of IVIg was used for conditions lacking convincing evidence of benefit, such as multiple sclerosis and inclusion body myositis.
• Positive responses were most common in myasthenia gravis, Guillain-Barre syndrome, multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy.

Conclusions:

• IVIg use frequently deviated from Australian guidelines for neurological conditions.
• International guideline variations and limited studies for rare conditions complicate IVIg management.